Artelo Biosciences’ (ARTL) Buy Rating Reaffirmed at D. Boral Capital

Artelo Biosciences (NASDAQ:ARTL)‘s stock had its “buy” rating reaffirmed by D. Boral Capital in a research report issued on Monday,Benzinga reports. They presently have a $6.00 price objective on the stock. D. Boral Capital’s price target would suggest a potential upside of 468.72% from the company’s previous close.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $5.00 price objective on shares of Artelo Biosciences in a research note on Tuesday, March 4th.

Artelo Biosciences Stock Performance

Shares of NASDAQ:ARTL traded up $0.02 on Monday, reaching $1.06. The company’s stock had a trading volume of 20,175 shares, compared to its average volume of 133,619. The company has a 50-day simple moving average of $0.98 and a 200 day simple moving average of $1.09. Artelo Biosciences has a 52-week low of $0.82 and a 52-week high of $1.59. The company has a market cap of $3.46 million, a P/E ratio of -0.37 and a beta of 1.17.

Artelo Biosciences (NASDAQ:ARTL) last released its quarterly earnings results on Monday, March 3rd. The company reported ($1.17) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.43). On average, equities research analysts forecast that Artelo Biosciences will post -2.62 EPS for the current fiscal year.

Artelo Biosciences Company Profile

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.